ATE480521T1 - Stickstoff enthaltende heterocyclische verbindungen - Google Patents

Stickstoff enthaltende heterocyclische verbindungen

Info

Publication number: ATE480521T1
Authority: AT; Austria
Prior art keywords: substituted; atom; alkyl group; nitrogen atom; nitrogen
Prior art date: 1996-10-01

Application number

AT97943133T

Other languages

English (en)

Inventor

Kenji Matsuno

Michio Ichimura

Yuji Nomoto

Shigeki Fujiwara

Shinichi Ide

Eiji Tsukuda

Junko Irie

Shoji Oda

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-01

Filing date

1997-10-01

Publication date

2010-09-15

1997-10-01 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE480521T1 publication Critical patent/ATE480521T1/de

Links

229910052757 nitrogen Inorganic materials 0.000 title abstract 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
150000002391 heterocyclic compounds Chemical class 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 5
125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
-1 nitrogen-containing heterocyclic compounds Chemical class 0.000 abstract 3
125000002723 alicyclic group Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091008606 PDGF receptors Proteins 0.000 abstract 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
230000026731 phosphorylation Effects 0.000 abstract 1
238000006366 phosphorylation reaction Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyridine Compounds (AREA)
Quinoline Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

AT97943133T 1996-10-01 1997-10-01 Stickstoff enthaltende heterocyclische verbindungen ATE480521T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP26074396		1996-10-01
PCT/JP1997/003510 WO1998014431A1 (en)	1996-10-01	1997-10-01	Nitrogenous heterocyclic compounds

Publications (1)

Publication Number	Publication Date
ATE480521T1 true ATE480521T1 (de)	2010-09-15

Family

ID=17352137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97943133T ATE480521T1 (de)	1996-10-01	1997-10-01	Stickstoff enthaltende heterocyclische verbindungen

Country Status (13)

Country	Link
US (4)	US6169088B1 (de)
EP (1)	EP0882717B1 (de)
JP (1)	JP4073961B2 (de)
KR (1)	KR100622323B1 (de)
CN (1)	CN1169795C (de)
AT (1)	ATE480521T1 (de)
AU (1)	AU719392B2 (de)
CA (1)	CA2239227C (de)
DE (1)	DE69739986D1 (de)
DK (1)	DK0882717T3 (de)
ES (1)	ES2351684T3 (de)
NZ (1)	NZ330571A (de)
WO (1)	WO1998014431A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0880508T3 (da)	1996-02-13	2003-06-30	Astrazeneca Ab	Quinazolinderivater som VEGF-inhibitorer
CN1116286C (zh)	1996-03-05	2003-07-30	曾尼卡有限公司	4－苯胺基喹唑啉衍生物
ATE300521T1 (de)	1996-09-25	2005-08-15	Astrazeneca Ab	Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
ATE496035T1 (de) *	1998-03-31	2011-02-15	Kyowa Hakko Kirin Co Ltd	Stickstoffenthaltende heterocyclische verbindungen
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
DK1119567T3 (da)	1998-10-08	2005-07-25	Astrazeneca Ab	Quinazolinderivater
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
US6455734B1 (en)	2000-08-09	2002-09-24	Magnesium Diagnostics, Inc.	Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9919558D0 (en)	1999-08-18	1999-10-20	Hoechst Schering Agrevo Gmbh	Fungicidal compounds
JP2001131151A (ja) *	1999-11-02	2001-05-15	Shionogi & Co Ltd	オレフィン誘導体の新規用途
EP1676845B1 (de)	1999-11-05	2008-06-11	AstraZeneca AB	Neue Quinazolin-Derivate
ES2267748T3 (es)	2000-04-07	2007-03-16	Astrazeneca Ab	Compuestos de quinazolina.
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
CN100345830C (zh) *	2000-04-27	2007-10-31	安斯泰来制药有限公司	稠合杂芳基衍生物
DE60140868D1 (de)	2000-06-05	2010-02-04	Brigham & Womens Hospital	Für ein homologes des humanen, für mehrfachresistenz verantwortlichen, p-glykoproteins auf chromosom 7p15-21 kodierendes gen sowie verwendungen dafür
WO2001095856A2 (en) *	2000-06-15	2001-12-20	Chaconne Nsi Co., Ltd.	Urea derivative useful as an anti-cancer agent and process for preparing same
AU8066701A (en) *	2000-07-20	2002-02-05	Neurogen Corp	Capsaicin receptor ligands
ATE419245T1 (de)	2000-08-09	2009-01-15	Astrazeneca Ab	Cinnoline verbindungen
CN1315822C (zh)	2000-08-09	2007-05-16	阿斯特拉曾尼卡有限公司	具有vegf抑制活性的喹啉衍生物
EP1309567A2 (de) *	2000-08-18	2003-05-14	Millennium Pharmaceuticals, Inc.	Stickstoffhaltige heterozyklische verbindungen
MXPA03001359A (es) *	2000-08-18	2004-12-13	Millennium Pharm Inc	Derivados de quinazolina como inhibidores de cinasa.
ATE498614T1 (de)	2000-08-18	2011-03-15	Millennium Pharm Inc	(chinazolin-4-yl)piperazin-4-ylüthiocarboxamide als hemmer der phosphorylierung eines pdgf- rezeptors
ES2354039T3 (es) *	2000-08-18	2011-03-09	Millennium Pharmaceuticals, Inc.	Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr.
DE60144284D1 (de) *	2000-11-01	2011-05-05	Millennium Pharm Inc	Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US20040259881A1 (en) *	2001-02-02	2004-12-23	Anjali Pandey	Nitrogenous heterocyclic compounds
MXPA03007609A (es) *	2001-02-27	2004-06-30	Univ Michigan	Uso de inhibidores egfr naturales para evitar efectos secundarios debidos a terapia de retinoide, jabones y otros estimulos que activan el receptor del factor de crecimiento epidermico.
US6960580B2 (en)	2001-03-08	2005-11-01	Millennium Pharmaceuticals, Inc.	Nitrogenous heterocyclic substituted quinoline compounds
US6896949B1 (en)	2001-03-15	2005-05-24	Bookham (Us) Inc.	Wafer scale production of optical elements
BR0209957A (pt) *	2001-05-21	2004-03-30	Hoffmann La Roche	Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
US8124625B2 (en)	2001-09-14	2012-02-28	Shionogi & Co., Ltd.	Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6787558B2 (en)	2001-09-28	2004-09-07	Hoffmann-La Roche Inc.	Quinoline derivatives
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati
US7030115B2 (en)	2002-03-21	2006-04-18	Abbott Laboratories	N-sulfonylurea apoptosis promoters
EP1487811B1 (de) *	2002-03-21	2007-09-05	Abbott Laboratories	N-sulfonylurea-apoptosis-förderer
WO2004002960A1 (en)	2002-06-27	2004-01-08	Schering Aktiengesellschaft	Substituted quinoline ccr5 receptor antagonists
US7713983B2 (en)	2003-03-03	2010-05-11	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
CL2004000409A1 (es)	2003-03-03	2005-01-07	Vertex Pharma	Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
KR101218889B1 (ko)	2003-08-27	2013-01-11	옵쏘테크 코포레이션	안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
PL2210607T3 (pl) *	2003-09-26	2012-01-31	Exelixis Inc	N-[3-fluoro-4-({6-(metyloksy)-7-[(3-morfolin-4-ylopropylo)oksy]chinolin-4-ylo} oxy)fenylo]-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksamid do leczenia raka
CA2542076C (en) *	2003-10-14	2013-02-26	Arizona Board Of Regents On Behalf Of The University Of Arizona	Substituted tricyclic compounds as protein kinase inhibitors
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
WO2005097137A2 (en) *	2004-03-31	2005-10-20	The Scripps Research Institute	Advanced quinazoline based protein kinase inhibitors
US7928107B2 (en)	2004-09-02	2011-04-19	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
MX2007002592A (es) *	2004-09-03	2007-10-10	Memory Pharm Corp	Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
GB0503056D0 (en) *	2005-02-14	2005-03-23	Smithkline Beecham Corp	Chemical compounds
US7700595B2 (en)	2005-03-01	2010-04-20	Wyeth Llc	Cinnoline compounds
ES2319462T3 (es) *	2005-03-28	2009-05-07	Bristol-Myers Squibb Company	Inhibidores competitivos de atp cinasas.
US20090029982A1 (en) *	2005-04-28	2009-01-29	Supergen, Inc.	Protein kinase inhibitors
US7825244B2 (en)	2005-06-10	2010-11-02	Janssen Pharmaceutica Nv	Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en)	2005-06-10	2011-12-06	Janssen Pharmaceutica, N.V.	Alkylquinoline and alkylquinazoline kinase modulators
US20100179162A1 (en) *	2005-07-20	2010-07-15	Millennium Pharmaceuticals , Inc.	Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide
AU2013211455B2 (en) *	2005-09-19	2017-12-07	Neuronascent, Inc.	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
AU2007217474A1 (en) *	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
EP1991530A1 (de) *	2006-02-21	2008-11-19	Amgen Inc.	Cinnolinderivate als phosphodiesterase-10-hemmer
MX2008010953A (es) *	2006-02-28	2008-09-08	Amgen Inc	Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
US20090099175A1 (en) *	2006-03-01	2009-04-16	Arrington Mark P	Phosphodiesterase 10 inhibitors
JP2009529060A (ja) *	2006-03-08	2009-08-13	アムゲンインコーポレイティッド	ホスホジエステラーゼ１０阻害剤としてのキノリン及びイソキノリン誘導体
US8106071B2 (en) *	2007-02-21	2012-01-31	Biobud Co., Ltd.	Compositions for treating hyperproliferative vascular disorders and cancers
CN101679313A (zh) *	2007-04-13	2010-03-24	休普基因公司	用于治疗癌症或过度增殖性疾病的axl激酶抑制剂
DK2364185T3 (da) *	2008-11-03	2013-06-03	Lilly Co Eli	Disubstituerede phthalazin-hedgehog-pathway-antagonister
JP2012509321A (ja) *	2008-11-21	2012-04-19	ミレニアムファーマシューティカルズ，インコーポレイテッド	癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物
US8877776B2 (en)	2009-01-16	2014-11-04	Exelixis, Inc.	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
EP2400985A2 (de)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2518064A1 (de) *	2009-12-25	2012-10-31	Mochida Pharmaceutical Co., Ltd.	Neues arylharnstoffderivat
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
ES2671748T3 (es)	2011-07-21	2018-06-08	Tolero Pharmaceuticals, Inc.	Inhibidores heterocíclicos de proteína quinasas
EP2771011A4 (de)	2011-10-24	2015-04-15	Glaxosmithkline Ip No 2 Ltd	Chemische verbindungen
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
CA2891926A1 (en) *	2012-11-20	2014-05-30	Merial, Inc.	Anthelmintic compounds and compositions and method of using thereof
CN103601722B (zh) *	2013-09-13	2016-03-02	南京华威医药科技开发有限公司	新型抗肿瘤化合物
MA41169A (fr) *	2014-12-17	2017-10-24	Acraf	Composés antibactériens à large spectre d'activité
CA3018537C (en) *	2016-03-21	2025-04-22	Council Of Scientific & Industrial Research	Signal blocking by TLR9 (Toll-like receiver 9) with a small molecule antagonist
CN108191756B (zh) *	2017-12-12	2020-08-25	绍兴文理学院	一种喹啉衍生物及其制备方法和应用
SG11202009443RA (en)	2018-04-05	2020-10-29	Sumitomo Dainippon Pharma Oncology Inc	Axl kinase inhibitors and use of the same
JP7662528B2 (ja)	2019-02-12	2025-04-15	スミトモファーマアメリカ，インコーポレイテッド	複素環式タンパク質キナーゼ阻害剤を含む製剤
CN115108999B (zh) *	2019-07-26	2023-11-03	暨南大学	一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
KR102260675B1 (ko) *	2019-07-30	2021-06-07	주식회사 하임바이오	신규한 항암용 화합물, 및 이를 유효성분으로 포함하는 약학조성물
WO2023280317A1 (zh) *	2021-07-09	2023-01-12	南京明德新药研发有限公司	苄氨基三并环类化合物及其应用
CN115677702B (zh) *	2021-07-23	2024-07-02	武汉誉祥医药科技有限公司	三并环化合物及其药物组合物和应用
CN117482096A (zh) *	2023-11-17	2024-02-02	右江民族医学院附属医院	Lf3在制备治疗关节炎药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3723434A (en) *	1970-07-17	1973-03-27	Pfizer	Piperazino isoquinoline bronchodilators
JPS58172379A (ja) *	1982-04-02	1983-10-11	Showa Denko Kk	新規なキナゾリン誘導体
JPS60120872A (ja) *	1983-12-01	1985-06-28	Kyowa Hakko Kogyo Co Ltd	新規なヘテロ環状化合物及び強心剤
JPH02167277A (ja) *	1988-09-19	1990-06-27	Kyowa Hakko Kogyo Co Ltd	新規なジアジン化合物
DK0584222T3 (da) *	1991-05-10	1998-02-23	Rhone Poulenc Rorer Int	Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
JP3229693B2 (ja) *	1993-02-22	2001-11-19	協和醗酵工業株式会社	ピペラジン誘導体
US5661147A (en) *	1993-09-03	1997-08-26	Kyowa Hakko Kogyo Co., Ltd.	Imidazoquinazoline derivatives
FR2722788B1 (fr) *	1994-07-20	1996-10-04	Pf Medicament	Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
US5701492A (en) *	1996-03-29	1997-12-23	Canon Kabushiki Kaisha	Fail-safe flashing of EPROM

1997
- 1997-10-01 JP JP51638098A patent/JP4073961B2/ja not_active Expired - Fee Related
- 1997-10-01 AT AT97943133T patent/ATE480521T1/de active
- 1997-10-01 DE DE69739986T patent/DE69739986D1/de not_active Expired - Lifetime
- 1997-10-01 DK DK97943133.5T patent/DK0882717T3/da active
- 1997-10-01 EP EP97943133A patent/EP0882717B1/de not_active Expired - Lifetime
- 1997-10-01 ES ES97943133T patent/ES2351684T3/es not_active Expired - Lifetime
- 1997-10-01 WO PCT/JP1997/003510 patent/WO1998014431A1/ja not_active Ceased
- 1997-10-01 CA CA002239227A patent/CA2239227C/en not_active Expired - Fee Related
- 1997-10-01 KR KR1019980704125A patent/KR100622323B1/ko not_active Expired - Fee Related
- 1997-10-01 AU AU44708/97A patent/AU719392B2/en not_active Ceased
- 1997-10-01 NZ NZ330571A patent/NZ330571A/xx not_active IP Right Cessation
- 1997-10-01 CN CNB971917418A patent/CN1169795C/zh not_active Expired - Fee Related
1998
- 1998-06-01 US US09/088,199 patent/US6169088B1/en not_active Expired - Lifetime
2000
- 2000-01-12 US US09/481,544 patent/US6207667B1/en not_active Expired - Lifetime
- 2000-12-13 US US09/734,918 patent/US6472391B2/en not_active Expired - Lifetime
2002
- 2002-08-26 US US10/227,302 patent/US6750218B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1998014431A1 (en)	1998-04-09
CA2239227A1 (en)	1998-04-09
NZ330571A (en)	1999-10-28
US20030229077A1 (en)	2003-12-11
CA2239227C (en)	2007-10-30
CN1208404A (zh)	1999-02-17
ES2351684T3 (es)	2011-02-09
AU4470897A (en)	1998-04-24
JP4073961B2 (ja)	2008-04-09
AU719392B2 (en)	2000-05-11
HK1016174A1 (en)	1999-10-29
EP0882717A4 (de)	2002-06-19
CN1169795C (zh)	2004-10-06
US20020068734A1 (en)	2002-06-06
EP0882717A1 (de)	1998-12-09
US6472391B2 (en)	2002-10-29
US6207667B1 (en)	2001-03-27
DK0882717T3 (da)	2010-12-13
EP0882717B1 (de)	2010-09-08
US6750218B2 (en)	2004-06-15
US6169088B1 (en)	2001-01-02
KR19990071843A (ko)	1999-09-27
KR100622323B1 (ko)	2006-11-30
DE69739986D1 (de)	2010-10-21

Legal Events

Date

Code

Title

Description

2011-03-15

UEP

Publication of translation of european patent specification

Ref document number: 0882717

Country of ref document: EP

Publication	Publication Date	Title
ATE480521T1 (de)	2010-09-15	Stickstoff enthaltende heterocyclische verbindungen
ATE496035T1 (de)	2011-02-15	Stickstoffenthaltende heterocyclische verbindungen
DE69428476D1 (de)	2001-11-08	Heterocyclische Verbindungen als Bradykinin Antagonisten
ATE541833T1 (de)	2012-02-15	Stickstoff-enthaltende verbindungen mit kinasehemmender wirkung sowie diese enthaltende medikamente
ATE123771T1 (de)	1995-06-15	Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
DE69232022D1 (de)	2001-10-04	Naphthyridinderivate als Angiotensin-II-Antagonist-Inhibitoren
BR9408442A (pt)	1997-08-05	Composto composição farmacêutica processos para tratamento ou prevenção de distúrbios fisiológicos associados com um excesso de taquiquininas e para a preparação do composto e de uso do composto
HUP0001446A2 (hu)	2001-05-28	HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények
ATE105554T1 (de)	1994-05-15	Benzazol-derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
DE69015239D1 (de)	1995-02-02	Chinolinon-Derivate, Verfahren zu ihrer Herstellung und diese Derivate enthaltende antibakteriell wirkende Mittel.
DE3750111D1 (de)	1994-07-28	Substituierte Phenyl-2-propensäure Derivate und ihre Verwendung als Fungizide.
DE69428142D1 (de)	2001-10-11	Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
DE69131759D1 (de)	1999-12-09	An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one
DK0609289T3 (da)	1996-11-25	Imidazolderivater og farmaceutiske præparater med indhold deraf
ATE147625T1 (de)	1997-02-15	Hydantoin- oder imidazolidintrionderivate zur vorbeugung oder behandlung von niereninsuffizienz
DE69416235D1 (de)	1999-03-11	Triazin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE240949T1 (de)	2003-06-15	Epoxysuccinamid-derivate oder ihre salze
DE3764077D1 (de)	1990-09-06	Zentralwirkende muskelrelaxante.
EP0798298A4 (de)	1998-03-25	Thiazolidinon-verbindungen oder heilmittel oder vorbeugemittel zur behandlung von angina pectoris das diese als wirkstoffe enthält
ATE205209T1 (de)	2001-09-15	Chinolincarbonsäurederivate und ihre salze
EP0299076A4 (en)	1991-01-09	5-hydroxyindole-3-carboxamide compound and medicinal use thereof
ES2084120T3 (es)	1996-05-01	Medicamentos para prevenir y tratar enfermedades del aparato circulatorio que contienen compuestos de espiro-3-heteroazolidina.
ATE169015T1 (de)	1998-08-15	Aminobenzoesäure derivate
EP0990645A4 (de)	2002-01-02	Neue sulfonamid-derivate
ATE27455T1 (de)	1987-06-15	Heterocyclische guanidino-phenylamidine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.